

September 2, 2003

MEDICAID DRUG REBATE PROGRAM

RELEASE #125

For State Medicaid Directors

OPERATIONAL TRAINING GUIDE REVISIONS

Attached are revised pages (G4, G6-7, G11-14, H4, I2, N3, S8) to the Operational Training Guide. Also, a new page (F10c) has been added to the guide. These pages are being issued to clarify, change, and/or add additional information to the guide. Please share these revisions with staff responsible for drug rebate functions and replace them in your guide.

NEW LABELERS

<u>Labeler Name/Labeler Code</u>	<u>Mandatory Coverage Date</u>	<u>Optional Coverage Date</u>
QOL Medical (Labeler Code 67871)	10/01/2003	07/23/2003
Vision Pharma, LLC (Labeler Code 68013)	10/01/2003	08/01/2003
River's Edge Pharmaceuticals (Labeler Code 68032)	01/01/2004	08/05/2003
Ovation Pharmaceuticals, Inc. (Labeler Code 67386)	01/01/2004	08/18/2003
Palmetto Pharmaceuticals Inc. (Labeler Code 68134)	01/01/2004	08/23/2003

REINSTATED LABELER

C.O. Truxton, Inc., (Labeler Code 00463) has signed a new rebate agreement and will be reinstated in the drug rebate program effective October 01, 2003.

Contact information for the new/reinstated labelers is attached for your convenience.

TERMINATED LABELER

The following labeler code is being voluntarily terminated effective January 1, 2004:

Horus Therapeutics (Labeler Code 59229).

OTHER ATTACHMENT

A copy of the current listing of the 90-day treasury bill auction rates beginning with the period April 22, 2002, is attached.

Please remember to direct your drug rebate questions to a staff member listed in section “O” of the Medicaid Drug Rebate Operational Training Guide.

/s/

Wayne Smith
Acting Director
Finance, Systems and Budget Group
Center for Medicaid and State Operations

3 Attachments

cc:

All State Drug Rebate Technical Contacts
All Regional Administrators

Multiple Package Size Products and Data Requirements

Baseline Data Fields – 9-digit NDC (same for all package sizes):

1. Drug Category
2. Therapeutic Equivalence Code
3. DESI Indicator
4. Date Entered Market
5. Unit Type
6. FDA Approval Date
7. Drug Type
8. Baseline AMP (for S & I drugs marketed before 10/1/1993)

Baseline Data Fields – 11-digit NDC (unique to each package size):

1. NDC 3
2. UPPS
3. Product Name
4. Termination Date

Quarterly Pricing Data (same for all package sizes):

1. AMP (weighted)
2. BP (for S & I drugs)

Facts regarding multiple package size products:

- As new package sizes are added, pricing data and URAs are back-filled with the information from the oldest marketed package size for uniformity of data.
- Common baseline data fields (shown above) for multiple package size products will be automatically aligned with the information from the oldest marketed package size.
- Pricing changes affect ALL package sizes due to weighting. Changes to Date Entered Market and/or Baseline AMP will cause all package sizes to recalculate.
- Individual records for package sizes will not be allowed. There will be one common record for each product and one pricing (history) record for each package size.

(Before and After the URA Calculations)

B E F O R E . . .

When necessary, edit reports are sent to labelers with an introductory letter explaining what to look for and what to do with data causing “alert” messages, as well as data that actually “rejects.” Labelers are asked to make corrections and resubmit the data using the same transmission medium used for the original data submission.

The edit report shows messages for both rejected and alerted records. Records that reject will do so for a number of reasons. If a quarterly pricing record rejects, it would be due to:

- ♥ AMP/BP not numeric
- ♥ AMP/BP missing
- ♥ Product record not on MDRI (NDC does not exist on CMS’s file)
- ♥ Different package sizes (NDC 3) of a product (NDC 2) with different AMP or BP values.

If a Baseline record rejects, it would be for:

- ♥ Field not within specific range (e.g., DESI not between 2 & 6, Unit Type not valid)
- ♥ Numeric field not numeric
- ♥ Market Date/ FDA Approval Date missing (see explanation below)
- ♥ Baseline AMP missing for Market Date < 10-01-93
- ♥ Baseline change (Correction Flag = “1”) with no match on MDRI
- ♥ Baseline addition (Correction Flag = “0”), NDC already exists on MDRI
- ♥ Baseline Field(s) (Unit Type, Drug Category, Drug Type, DESI, Therapeutic Equivalent, Market Date, FDA Approval Date) on one package size (NDC 3) not equal to field on established product (NDC 2)

σ BP greater than AMP

In general, the definition of BP is that it is the lowest price at which a labeler sold its drug for the quarter. Therefore, BP can not be higher than other prices paid. AMP can occasionally be calculated as actually lower than Best Price. (See section F for more information.) In this instance, labelers make the BP **EQUAL TO AMP** (i.e., lower the BP) for the quarter. Again, **this record is NOT rejected**; however, labelers should make a correction prior to or with their next quarter's pricing data submission.

σ DESI change attempted

CMS breaks both DESI and non-DESI drugs into specific categories. The values of "2", "3", and "4" are used for (non-DESI) drugs that will be covered by the program; values of "5" and "6" are used for (DESI) drugs that are not covered (refer to the Quarterly Pricing Data Definitions in section F for more specifics). All drugs are to be reported to CMS regardless of whether they are DESI drugs or not.

CMS verifies all MDRI records that are designated as DESI (codes "5" or "6") with the FDA. This assures that the DESI indication carried on the MDRI file agrees with the FDA master file. **If labelers attempt to change a DESI code, an alert message will be generated and the change will NOT be made.** **Labelers are told to change their system's DESI record back to the original value.**

RESERVED

FOR

FUTURE USE

*** * * N O T I C E * * ***

data edit report

Attached is an edit listing of your latest Product/Pricing data submittal. Please review and follow the instructions below.

- 1.) Review any messages stating that **BP** is greater than **AMP**. If, in a given quarter, an **AMP** computes less than **BP**, due to large discounts or unusually high level of returns, **BP** **MUST** be lowered to equal **AMP**. The system has done this automatically. Please correct this record on your file.
- 2.) There may be **ALERT** messages stating that you attempted to change a **DESI** value. Once baseline data has been established, the **DESI** code can only be changed **UNDER DIRECTION OF THE FDA** and by a CMS Operations analyst. This change **DID NOT** take.
- 3.) For **PRODUCT DATA MISSING** rejects, it means that the **ENTIRE BASELINE (PRODUCT) RECORD MUST BE** re-reported, as it is **NOT** established on our master file.
- 4.) For **"REGULAR REJECTS"**, please follow the message. There is probably either an incorrect or unacceptable value.
- 5.) For **REJECTS** dealing with **Market** and **FDA Approval Dates**, please remember that their inclusion with the Baseline data became mandatory with OBRA'93.
- 6.) For multiple package size errors, please note that **ONLY Termination Date, Product Name, and Units Per Package Size** fields may be different. All other fields (including AMP and BP) **MUST** be the same for ALL package sizes of a given product. Follow all multiple package size messages carefully.

REJECT corrections must be submitted using your normal method of data submission. Correcting rejects on the attached listing and returning to us **WILL NOT CORRECT THE ERROR. ALL ERRORS ARE REJECTED BY THE SYSTEM AND MUST BE RESUBMITTED ENTIRELY BY YOU.** **BP** corrections (**ALERTS ONLY**) have already been changed on our system and must be duplicated on your system.

Please refer to Section G, of your Operations Guide for additional information. If you have any questions, please refer to section O of your Operations guide for a list of Operations analysts.

Vince Powell, Technical Director
Drug Rebate Operations
CMS/CMSO/FSBG/DSS

**** ATTENTION REQUIRED ****
(NO QUARTERLY PRICING DATA REPORT)

Enclosed is a listing of your drug products for which we did not receive prices for the calendar quarter shown. Unit Rebate Amounts (URAs) equal to zero were reported on the state files; therefore, you will have to calculate URAs and include a ROSI with your payment to each state.

If any of these NDCs have been terminated for more than four quarters, please send us a valid Termination Date. NDCs appearing on this listing either **DO NOT** contain termination dates or have termination dates less than four quarters old. Please remember that prices are due for four quarters **BEYOND** the actual quarter of termination or shelf life.

If this report contains 15 or fewer NDCs, please annotate price or termination date corrections and mail to:

Drug Rebate Operations
c/o CMS/CMSO/FSBG/DSS
P.O. Box 26686
Baltimore, Md 21207-0486

ATTN: Christene Holmes
Mail Stop S3-13-15

If there are more than 15 NDCs, please submit price/date corrections **WITH** or **BEFORE** your next quarterly submission using your ***NORMAL MODE OF SUBMISSION***.

Please **DO NOT FAX** this information to us.

If you have any questions, please refer to the Operations Guide (section O) for a list of Operations analysts.

Thank you,

Vince Powell, Technical Director
Drug Rebate Operations
CMS/CMSO/FSBG/DSS

***** ATTENTION REQUIRED *****
(NO REBATES - DATA ERRORS)

When OBRA'93 was enacted, values used for Unit Rebate Amount (URA) calculations were changed. For "S" & "I" drugs having a **MARKET DATE** \geq 10-01-90, the 'additional rebate' calculation, for quarters **STARTING WITH 4-93**, is performed using the **CALCULATED AMP** for the **first full quarter** the product was on the market **IN PLACE OF** the BL/AMP. Thus, pricing (BOTH AMP/BP) for the NDCs indicated **FOR THE SPECIFIC QUARTERS REPORTED** on the enclosed report must be reported to us. This may require you to supply prices for an NDC for a quarter **prior to your starting in the rebate program**.

If there are 15 or fewer items for correction, please handwrite corrections on the listing and send it to us at the following address. If there are more than 15 corrections, please use your **NORMAL MODE FOR DATA SUBMISSION**.

Drug Rebate Operations
Holmes
c/o CMS/CMSO/FSBG/DSS
P. O. Box 26686
Baltimore, Md. 21207-0486

ATTN: Christene

Mailstop S3-13-15

Please **DO NOT FAX** this information to us.

If you have any questions, please refer to the Operations Guide (section O) for a list of Operations analysts.

Thank you,

Vince Powell, Technical Director
Drug Rebate Operations
CMS/CMSO/FSBG/DSS

***** ATTENTION REQUIRED *****
(50/50 REPORT)

Some of your active reported NDCs from the current quarter have been reported to the States as zero, **EVEN THOUGH YOU SUBMITTED YOUR PRICING DATA ON TIME!!** This occurs when the URA for a given NDC for this quarter is calculated to be more than 50% different (+ or -) from last quarter.

Attached is a listing of your NDCs that match this scenario. Enough historical data is included (Baseline AMP, Market Date, Last Quarter AMP/BP, etc.) for you to evaluate the problem and make corrections where applicable. If pricing is correct, **DO NOT NOTIFY US. NEXT QUARTER, CMS WILL REPORT THIS URA TO THE STATES AS A PPA. USE THE CALCULATED URA AT THE FAR RIGHT COLUMN AND COMPUTE TOTAL REBATE OWED FOR THIS NDC TO BE INCLUDED IN YOUR TOTAL REBATE TO THE STATES.** If a correction to AMP or BP is necessary, please recalculate the per unit rebate using the correct pricing and submit your rebate to the States using the CORRECTED URA. Also include a ROSI with your check to each state.

Please submit the same AMP/BP corrections to CMS with or before your next quarterly submission, using your ***NORMAL MODE FOR DATA SUBMISSION***. If there are 15 or fewer corrections to be made, you may wish to annotate them on the listing and return to:

Drug Rebate Operations ATTN: Christene Holmes
c/o CMS/CMSO/FSBG/DSS Mailstop S3-13-15
P.O. Box 26686
Baltimore, Md. 21207-0486

Please **DO NOT FAX** this information to us.

If you have any questions, please refer to the Operations Guide (section O) for a list of Operations analysts.

Thank you,

Vince Powell, Technical Director
Drug Rebate Operations
CMS/CMSO/FSBG/DSS

Several values are required to complete the additional URA calculation:

- υ Quarterly AMP;
- υ Baseline AMP and Baseline CPI-U; and
- υ Quarterly CPI-U.

Quarterly CPI-U is always the CPI-U value of the month prior to the quarter being calculated. The Baseline CPI-U value used varies depending on the product's Market Date. A quick reference for Baseline CPI-U is given in the following chart (more information on Baseline values is found further in this section).

Quarter	Market Date	Baseline AMP	Baseline CPI-U
93-4 (4 th Qtr. 1993) to present	Greater than 9/30/93	AMP for 1 st Qtr. After Market Date	CPI-U for month prior to 1 st Qtr. after Market Date
93-4 to present	Greater than 9/30/90; less than 10/1/93	AMP for 1 st Qtr. After Market Date	CPI-U for month prior to 1 st Qtr. after Market Date
91-1 through 93-3	Greater than 9/30/90; less than 10/1/93	AMP for 1 st day of 1 st full month on the market	CPI-U for the month before 1 st full month
91-1 through present	Equal or less than 09/30/90	90-3 AMP	132.7 (value for 9/90)

Perform the following calculations.

- a) Baseline AMP/Baseline CPI-U
- b) Result of “a)” * quarter’s CPI-U
- c) **If result of “b)” is less than AMP**, subtract result from quarter’s AMP to get the additional URA.

If result of “b)” is equal to or greater than the quarter’s AMP, there is no additional URA to apply.

Total URA for “S” and “I” Drugs

Add any additional URA to the basic URA from step one for the total URA.

INTEREST CALCULATION

The following is an overview of the interest provisions of the Medicaid Drug Rebate program. The rebate agreement requires that interest be paid or credited, when due, by the labeler or the state. For purposes of section V(b) of the National Drug Rebate Agreement, the interest rate, as specified in section 1903(d)(5) of the Act, is used. The interest rate is based on the yield of the weekly 90-day Treasury bill auction rates. The investment yield is considered the bond equivalent rate or the true discount rate.



Auctions of 90-day Treasury bills are generally held each Monday. If Monday is a holiday, the Treasury Department decides whether to hold the auction on the preceding Friday or the following Tuesday. Information on the T-Bill rates is provided to states and labelers in two ways: 1) it is on the Medicaid drug rebate website at www.cms.hhs.gov/Medicaid/drugs/drughmpg.asp and is updated monthly (current month is NOT on the web); and 2) it is included in periodic state and labeler releases.

Interest Due States

1. States are due interest on all unpaid disputed rebate payments that are resolved in the state's favor through dispute resolution. A **dispute** occurs when a labeler disagrees on a specific number of its drug's units reported by the state, and provides detailed written notification of the dispute in writing. A labeler that has not paid for the disputed units that are resolved in the state's favor must pay interest that begins accruing on the 38th calendar day from the date the state receives notification from the labeler as evidenced by the postmark. Interest stops accruing and is calculated up to the postmark date of the labeler's mailed check.

To avoid paying interest on disputes resolved in the state's favor, CMS encourages labelers to pay for disputed units timely. (See section K of the guide for more information on the dispute program.)

OBTAINING COPIES OF PROGRAM RELEASES

Generally, within a week of issuing a release to either state agencies or drug labelers, CMS uploads the release to the INTERNET.

For states, labelers, and private individuals with access to the Internet, the program releases are available at:

www.cms.hhs.gov/Medicaid/drugs/drughmpg.asp

.NOTE: CMS no longer provides the drug rebate releases for incorporation to the CD-ROM.

The following pages show examples of the text of a state and labeler release.

- Q: I got an invoice from a state and one of the NDCs has a zero URA. Do I ignore that one and just pay for the URAs that have an amount?
- A: No. Your responsibility is to pay rebates on all valid NDCs reported to you by a state. If an NDC has zeros in the URA it is due to one of several reasons: 1) You did not report pricing to us on time for this quarter; 2) You reported pricing but it was rejected and you haven't had time to turn around a correction from the edit list; or 3) You reported pricing but when the URA was calculated it was more than 50% higher or more than 50% lower than the last quarter. In case #3, you should have received a 50/50 report showing NDCs that fall into this category. If the pricing you submitted was, in fact, correct, use the URA shown as the very last data element on the 50/50 report for computing the rebate to the state. If the prices you reported are wrong, calculate the URA using correct pricing, use the correct URA for paying the state, and send a correction record to us with your next quarter's pricing submission. (See sections F and G)

WEEKLY U.S. T-BILL DISCOUNT RATE

weekly 90-day treasury bill auction rates

Date of Auction	Discount Rate	Date of Auction	Discount Rate	Date of Auction	Discount Rate
04-22-02	1.720	11-18-02	1.227	06-16-03	0.854
04-29-02	1.760	11-25-02	1.228	06-23-03	0.830
05-06-02	1.773	12-02-02	1.231	06-30-03	0.903
05-13-02	1.781	12-09-02	1.215	07-07-03	0.907
05-20-02	1.760	12-16-02	1.219	07-14-03	0.895
05-28-02	1.760	12-23-02	1.207	07-21-03	0.911
06-03-02	1.752	12-30-02	1.207	07-28-03	0.964
06-10-02	1.752	01-06-03	1.207	08-04-03	0.964
06-17-02	1.732	01-13-03	1.199	08-11-03	0.960
06-24-02	1.712	01-21-03	1.179	08-18-03	0.964
07-01-02	1.719	01-27-03	1.159	08-25-03	0.997
07-08-02	1.724	02-03-03	1.175		
07-15-02	1.712	02-10-03	1.171		
07-22-02	1.692	02-18-03	1.179		
07-29-02	1.712	02-24-03	1.195		
08-05-02	1.627	03-03-03	1.198		
08-12-02	1.659	03-10-03	1.077		
08-19-02	1.659	03-17-03	1.137		
08-26-02	1.661	03-24-03	1.174		
09-03-02	1.639	03-31-03	1.121		
09-09-02	1.676	04-07-03	1.158		
09-16-02	1.692	04-14-03	1.186		
09-23-02	1.639	04-21-03	1.182		
09-30-02	1.566	04-28-03	1.141		
10-07-02	1.615	05-05-03	1.117		
10-15-02	1.659	05-12-03	1.089		
10-21-02	1.696	05-20-03	1.040		
10-28-02	1.578	05-28-03	1.121		
11-04-02	1.433	06-02-03	1.133		
11-12-02	1.211	06-09-03	1.024		

TOPICAL INDEX - STATE MEDICAID RELEASES 1 - 125

TOPIC	RELEASE #
1A Drug Listing	11
Additional Copies of Releases to SMDs	40
Adjustment Code for Forms CMS-304 & CMS-304a	57
Allscrips Pharmaceuticals, Inc.	65, 68, 69
AMP Recalculations	107, 109, 110, 112
Bankruptcy - Drug Labelers	19, 61, 68
Best Price to DSH Covered Entities	36
Betaseron - Coverage & Reimbursement	38, 40
Bulk Transfer/Buy-Out of Major Pharm. Assets	54, 55
Calphron	76, 79
Caverject Coverage	55
Closure During Federal Furloughs	57
Compendia	70
Confidential Information Release	17
Constant Disputes by Drug Labelers	23
Contact Information	65, 92
CPI-U Information	09, 102
Dataset Name Changes on Quarterly Rebate Tapes	41
Deleted NDCs (non-rebatable)	123
Dipyridamole Issue	26
Dispute Resolution:	
Definition	19
Issues	55, 65, 71, 86, 108
Meetings	100, 104, 113, 117, 123
Process Stages	45
Transfer of Function	121
Web Site	122
Workgroup Survey Results	42
Dispute Resolutions	59
Drug Category Change	61, 76
Drug Efficacy Study & Implementation (DESI):	
Change Effective Date	20
Change Schedule	18
Effective Date Revisions	23, 24
DRUGDEX, a new compendium	70
Drug Emporium, Inc. Effective Date	65
Duplicate Discount/Rebate Mechanism Implementation	33
Effective Date(s) of Rebate Agreements	97
Enteral Nutritional Products - Coverage	30
Enteral Products	19
Eon Labs Product	117
Experimental Drugs - Coverage	43
Failure of Manufacturers to Notify States of	
Disputes or Pay Rebates	63
FDA/MDRI Data Match	107, 115
Generic Substitution Laws	67
TOPIC	RELEASE #

Goldline OTC Vitamin	102
Haldol Rebates	75
Herceptin: Genentech New Product	85
HIPPA – Prescription Numbers	124
Hotline	53
HRSA Notice Published/Exclusion File	98, 101, 106
Improper Rebate Withholding/Interest Implications	114
Index for Drug Rebate Notes	31
Information Sharing	57
Interest Calculation under Section V(b)	29, 88, 98
Interest:	
Failure to Pay	65
When PPAs are Submitted	121
Internet:	
Home Page	61, 85, 105, 117
Prescription Reimbursement Information	123
Pharmacy Plus Demonstrations	123
Invoices:	
Correct Labeler Address	36
Format	03
Incomplete Drug Labeler Data	18
Incorrect Invoicing	26
Remittance Advice Report Survey	35
Submission	19
Submitting for Multiple Quarters	36
Submitting to Drug Labelers	28
Labeler Contact File Changes	26, 32
Lovenox Prefilled Syringes	91
LTE/IRS Drugs	26
Magnetic Media	
New Address for Shipping (Effective 6/1/95)	52
Rejections	15
Shipments	15, 23
Specification Revisions	14, 72, 73
Manufacturer Information Record Specification	20
Manufacturer Name & Address Contact Info Diskette	27
MDR Technical E-mail Address	124
Medical Supplies & Devices	03, 16, 26
Metric Conversion/Rounding	18
Multiple Package Size-Pricing Inconsistency	123
New Drug Products	41
New Rebate Agreement Status	23
Novartis Rounding All URAs Back to 1991	117
OBRA '93	40
OIG Reports/Reviews	120
Overpayments Due to AMP Recalculations	57, 107
Personnel Changes	124
PHS Drug Pricing Program	44
TOPIC	RELEASE #

Point-of-Sale System (POS) in Pharmacies	85
Policy E-Mail Address	113, 117
Prior Authorization	55
Prior Period Adjustments	14, 16, 60, 87
Prior Period Adjustments - Eli Lilly & Company	37
Prior Quarter Adjustment Statement (PQAS) Approval	60
Proposed Discount Equal Access Legislation	51
Publication of Drug Rebate Regulations MB-46-P	55
Quarterly Prices, Late Submission	33
Quarterly Reporting - Form CMS-64.r	40
Quarterly Tape Submission to CMS	60, 72
Quarterly Update File	14
Questions and Answers	65
Rebate Agreements:	
Start Date Procedures	102
Separate/Supplemental	102
Rebate/Reimbursement Issues	64, 113
Rebates:	
Calculation Formula	07
Drugs Purchased Through the FSS	113
Less than Administrative Costs	40
Nonpayment	94
Partial Payments	55
Remittance/Check Address	30
Reconciliation of State Invoice (ROSI) Approval	60
Rejection of State Records Matching LTE Drugs	41
Remittance Advice Report/Workgroup	48, 52, 53, 56
Rescission of Termination for Novopharm USA	39
S-TAG (Systems Technical Advisory Group)	85
Separate Rebate Agreements with Manufacturers	38, 113
Special Advisory Group	16
Special Study – Anti-Load Viral/AIDS Drugs	102
Staff Listing	53
Staff Relocation	52, 83
Standard Summary Record Format	13
State Application of the FUL Program	48
State Contact Information	23, 26, 41, 98
State Coverage:	
LTE & IRS Drugs	40
Unit-Dose Drugs	19
State Data Validation Edits	33
State Hearing Process	44
State Invoices Containing Universal Product Codes	51
State Pharmacy Assistance Programs-Revised Criteria	124
State Plan Amendment Requirement	47
State Responsibility - Terminated Drugs	19
State Utilization Data Study (SUDS)	33
T-bill Rates	83, 86
TOPIC	RELEASE #

Terminated/Deleted Records	44
Termination From Program	55
Therapeutic Equivalency Code	64
Timely Receipt of Tapes/Notices of Mailing	45
Tolerance Threshold Clarification	
For Interest	48
Rebate Amount Adjustments	44
Training Guide	105, 109, 122, 124, 125
Unit-Dose Packaging	15
Unit Per Package Size	03
Change for Beohringer Ingelheim Product	123
Unit Rebate Amount (URA):	
Additional Amounts in 3/1998 File	85
Edits	43
Erroneous Amounts	51
Incorrect Amounts for 1Q98	79, 80
Invoice when the Amount is Zero	44
New Rounding Method	98, 100, 101, 106
Recalculations	111
Unit Type:	
Changes and Prior Period Adjustments	43
Conversion Date Changed	34
Revisions	32, 83
UPPS Less Than 1.0	19
UPPS Used for Calculating Utilization	61
Use of Information from Outside Sources	48
Utilization Adjustments for Prior Calendar Quarters	67, 72
Utilization Data:	
Changes to Labelers	57
Corrections/Problems	18, 51, 72
Late Submission	18
Receipt	29, 31
Record Format	08, 13, 72
Set Naming Requirements	19
Tapes/Confirmation Letter	19, 30, 40, 45, 58, 72, 82
Transmitting Corrections/Adjustments to CMS	16, 40, 72
Utilization Tape Record Specification	67, 72, 73, 98, 105
Vaccine:	
Deletions	26
Exclusions	19, 23
Policy Clarification	25
Viagra Coverage	81
Vitasert	64
Warrick Pharmaceuticals (Sodium Chloride Solution)	98
Xenical Coverage	97
Y2K	72, 87